Humacyte

Humacyte Long-term Debt

The Long-Term Debt of Humacyte (HUMA) as of Nov 21, 2026 is 35.44 M USD. In the previous year, Long-Term Debt was 38.60 M USD — a change of -8.18% (lower).

Long-term Debt

35.44 MUSD

YoY

-8.18%

Last updated:

Long-Term Debt of Humacyte is 2025 35.44 M USD. Long-Term Debt of Humacyte was 2024 38.60 M USD. It decreases by -8.18% lower compared to the previous year.

The Humacyte Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2020
822,000.00 USD
Jan 1, 2021
27.36 M USD
Jan 1, 2022
20.34 M USD
Jan 1, 2023
38.60 M USD
Jan 1, 2025
35.44 M USD
The Humacyte Long-term Debt history
YEARLong-term DebtYoY
35.44 MUSD-8.18%
38.60 MUSD+89.81%
20.34 MUSD-25.68%
27.36 MUSD+3,228.59%
822,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Long-Term Debt of Humacyte is 35.44 M USD in 2025.

Long-Term Debt of Humacyte changed from 38.60 M USD to 35.44 M USD, representing a -8.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Humacyte since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Humacyte historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humacyte

All Key Metrics — Humacyte